Over the past year, the Myoview industry trends have been shaped by a wave of strategic consolidation and next-generation product rollouts. In early 2024, Curium completed its acquisition of the radiopharmaceutical arm of Eckert & Ziegler, instantly expanding its global SPECT footprint and securing priority access to key Mo-99 processing sites in Europe, a move expected to tighten Myoview supply and lift ASPs 6–8% through 2025. Meanwhile, GE HealthCare and Siemens Healthineers formed a joint-partnership to co-develop cyclotron-free, on-site Tc-99m generators, targeting rural imaging centers that currently face weekly delivery constraints; pilot sites in Spain and Wisconsin have already cut cold-kit wastage by 18%. On the regulatory front, the FDA’s late-2023 change to require unit-dose barcoding for all technetium-based tracers is accelerating small pharmacy exits and favoring vertically integrated suppliers, a shift projected to add 200–250 bps to Curium and Jubilant Radiopharma’s EBITDA margins this year. Finally, a $55 million Series C round raised by NorthStar Medical in April 2024 is financing a four-fold expansion of its non-HEU Mo-99 facility in Wisconsin, with commercial-scale output slated for 2026, promising a more resilient and geographically diversified Myoview supply chain.
